Bapcor nearly doubles SPP to accommodate increased shareholder demand

Bapcor nearly doubles SPP to accommodate increased shareholder demand

Serious demand for car parts retailer Bapcor's (ASX: BAP) share purchase plan (SPP) has encouraged the company's directors to nearly double the amount on offer.

Bapcor received applications for the SPP totalling $122 million from registered shareholders for the SPP.

As a result Bapcor has increased the size of the SPP from $30 million to $56 million today.

Approximately 12.8 million new shares will be issued under the SPP on 25 May 2020. These new shares will rank equally with existing Bapcor shares on issue.

The increased SPP follows a successful $180 million underwritten institutional placement completed on 17 April.

When the raise was announced in April the company said funds would be used to reduce its net debt position.

The capital raise was complementary to a range of cost saving initiatives implemented by the company to preserve and manage cash flow during the Covid-19 crisis, including closing stores in New Zealand, cutting executive salaries, eliminating discretionary expenditure, and asking landlords for rent relief.

In April Bapcor CEO and managing director Darryl Abotemy (pictured) thanked those for supporting Bapcor's plans for the future.

"We are very pleased with the demonstration of support shown by our shareholders and other institutional investors for the Placement," Abotemy said.

"We see the success of the Placement as a clear endorsement of Bapcor's strong and resilient business and our strengthened position to continue to execute our five year strategy and any other growth initiatives that may arise."

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Advertisement

Related Stories

Brisbane biotech to trial world-first COVID-19 immunotherapy treatment

Brisbane biotech to trial world-first COVID-19 immunotherapy treatment

Brisbane and Seattle-based biotechnology company Implicit Bioscie...

Federal Court finds Google misled consumers on data collection

Federal Court finds Google misled consumers on data collection

The Federal Court has found Google misled consumers about persona...

Redflow charging up ahead of next-gen battery launch

Redflow charging up ahead of next-gen battery launch

Redflow (ASX: RFX) is gearing up to launch the next generation of...

Mayne Pharma breakthrough as FDA approves new contraceptive with plant-based estrogen

Mayne Pharma breakthrough as FDA approves new contraceptive with plant-based estrogen

A bet made by Mayne Pharma (ASX: MYX) in 2019 has paid off today ...